Cargando…

Targeting Cellular Metabolism With CPI-613 Sensitizes Pancreatic Cancer Cells to Radiation Therapy

PURPOSE: Local tumor progression is a cause of significant morbidity and mortality in patients with pancreatic ductal adenocarcinoma (PDAC) with surgically unresectable disease. Novel and effective approaches to accomplish durable local control are urgently needed. We tested whether CPI-613 (devimis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Khan, Husain Yar, Kamgar, Mandana, Aboukameel, Amro, Bannoura, Sahar, Chung, Brian Y., Li, Yiwei, Hallak, Mohammed Najeeb Al, Philip, Philip A., Tsai, Susan, Luther, Sanjeev, Hall, William A., Azmi, Asfar S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Scientific Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9720358/ https://www.ncbi.nlm.nih.gov/pubmed/36479231 http://dx.doi.org/10.1016/j.adro.2022.101122

Ejemplares similares

Calcium Release-Activated Calcium (CRAC) Channel Inhibition Suppresses Pancreatic Ductal Adenocarcinoma Cell Proliferation and Patient-Derived Tumor Growth
por: Khan, Husain Yar, et al.
Publicado: (2020)

Connecting the Human Microbiome and Pancreatic Cancer
por: Sexton, Rachel E., et al.
Publicado: (2022)

Correction to: Connecting the human microbiome and pancreatic cancer
por: Sexton, Rachel E., et al.
Publicado: (2022)

Inhibitor of the Nuclear Transport Protein XPO1 Enhances the Anticancer Efficacy of KRAS G12C Inhibitors in Preclinical Models of KRAS G12C–Mutant Cancers
por: Khan, Husain Yar, et al.
Publicado: (2022)

KRAS G12D targeted therapies for pancreatic cancer: Has the fortress been conquered?
por: Bannoura, Sahar F., et al.
Publicado: (2022)

DNA-Methylation-Caused Downregulation of miR-30 Contributes to the High Expression of XPO1 and the Aggressive Growth of Tumors in Pancreatic Ductal Adenocarcinoma
por: Azmi, Asfar S., et al.
Publicado: (2019)

Targeting pancreatic cancer with combinatorial treatment of CPI-613 and inhibitors of lactate metabolism
por: Kumstel, Simone, et al.
Publicado: (2022)

The Metabolic Inhibitor CPI-613 Negates Treatment Enrichment of Ovarian Cancer Stem Cells
por: Bellio, Chiara, et al.
Publicado: (2019)

Non-Coding RNAs in Pancreatic Cancer Diagnostics and Therapy: Focus on lncRNAs, circRNAs, and piRNAs
por: Li, Yiwei, et al.
Publicado: (2021)

Anticancer Efficacy of KRAS(G12C) Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of KRAS(G12C)-Mutant Pancreatic and Lung Cancers
por: Khan, Husain Yar, et al.
Publicado: (2023)

Nuclear Export Inhibitor KPT-8602 Synergizes with PARP Inhibitors in Escalating Apoptosis in Castration Resistant Cancer Cells
por: Uddin, Md. Hafiz, et al.
Publicado: (2021)

Pre-clinical anti-tumor activity of Bruton's Tyrosine Kinase inhibitor in Hodgkin's Lymphoma cellular and subcutaneous tumor model
por: Muqbil, Irfana, et al.
Publicado: (2019)

CPI-613 rewires lipid metabolism to enhance pancreatic cancer apoptosis via the AMPK-ACC signaling
por: Gao, Lixia, et al.
Publicado: (2020)

Blockade of glutamine-dependent cell survival augments antitumor efficacy of CPI-613 in head and neck cancer
por: Lang, Liwei, et al.
Publicado: (2021)

PAK4-NAMPT Dual Inhibition as a Novel Strategy for Therapy Resistant Pancreatic Neuroendocrine Tumors
por: Mpilla, Gabriel, et al.
Publicado: (2019)

A Phase II Clinical Trial of CPI-613 in Patients with Relapsed or Refractory Small Cell Lung Carcinoma
por: Lycan, Thomas W., et al.
Publicado: (2016)

A phase 1 study of first-in-class agent CPI-613 in combination with FOLFIRINOX for metastatic pancreatic cancer
por: Alistar, Angela, et al.
Publicado: (2017)

Therapeutic potential of CPI-613 for targeting tumorous mitochondrial energy metabolism and inhibiting autophagy in clear cell sarcoma
por: Egawa, Yuki, et al.
Publicado: (2018)

Smart Design of Mitochondria-Targeted and ROS-Responsive CPI-613 Delivery Nanoplatform for Bioenergetic Pancreatic Cancer Therapy
por: Zhang, Yi-Mei, et al.
Publicado: (2021)

PAK4 and NAMPT as Novel Therapeutic Targets in Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, and Mantle Cell Lymphoma
por: Khan, Husain Yar, et al.
Publicado: (2021)

Pharmacologic treatment with CPI-613 and PS48 decreases mitochondrial membrane potential and increases quantity of autolysosomes in porcine fibroblasts
por: Mordhorst, Bethany R., et al.
Publicado: (2019)

Exportin 1 (XPO1) inhibition leads to restoration of tumor suppressor miR-145 and consequent suppression of pancreatic cancer cell proliferation and migration
por: Azmi, Asfar S., et al.
Publicado: (2017)

Evidence for a novel, effective approach to targeting carcinoma catabolism exploiting the first-in-class, anti-cancer mitochondrial drug, CPI-613
por: Guardado Rivas, Moises O., et al.
Publicado: (2022)

Hypoxia-Induced Aggressiveness of Pancreatic Cancer Cells Is Due to Increased Expression of VEGF, IL-6 and miR-21, Which Can Be Attenuated by CDF Treatment
por: Bao, Bin, et al.
Publicado: (2012)

Targeting XPO1 and PAK4 in 8505C Anaplastic Thyroid Cancer Cells: Putative Implications for Overcoming Lenvatinib Therapy Resistance
por: Khan, Husain Yar, et al.
Publicado: (2019)

Targeting Nuclear Exporter Protein XPO1/CRM1 in Gastric Cancer
por: Sexton, Rachel, et al.
Publicado: (2019)

Exosomal microRNA in Pancreatic Cancer Diagnosis, Prognosis, and Treatment: From Bench to Bedside
por: Uddin, Md. Hafiz, et al.
Publicado: (2021)

Nuclear retention of Fbw7 by specific inhibitors of nuclear export leads to Notch1 degradation in pancreatic cancer
por: Gao, Jiankun, et al.
Publicado: (2014)

Gastric Cancer Heterogeneity and Clinical Outcomes
por: Sexton, Rachel E., et al.
Publicado: (2020)

SMI of Bcl-2 TW-37 is active across a spectrum of B-cell tumors irrespective of their proliferative and differentiation status
por: Al-Katib, Ayad M, et al.
Publicado: (2009)

CPI Hard Disk System
Publicado: (2017)

Scotch 777 6250 CPI
Publicado: (2017)

Targeting the Nuclear Export Protein XPO1/CRM1 Reverses Epithelial to Mesenchymal Transition
por: Azmi, Asfar S., et al.
Publicado: (2015)

Hepatocellular Carcinoma: Surveillance, Diagnosis, Evaluation and Management
por: Elderkin, Jessica, et al.
Publicado: (2023)

An MDM2 antagonist (MI-319) restores p53 functions and increases the life span of orally treated follicular lymphoma bearing animals
por: Mohammad, Ramzi M, et al.
Publicado: (2009)

Liquid biopsy for therapy monitoring in early-stage non-small cell lung cancer
por: Nagasaka, Misako, et al.
Publicado: (2021)

Synthesis of 6,13-difluoropentacene
por: Tripp, Matthias W, et al.
Publicado: (2020)

Anti-tumor activity of selective inhibitor of nuclear export (SINE) compounds, is enhanced in non-Hodgkin lymphoma through combination with mTOR inhibitor and dexamethasone
por: Muqbil, Irfana, et al.
Publicado: (2016)

The Effect of Galangin on the Regulation of Vascular Contractility via the Holoenzyme Reactivation Suppressing ROCK/CPI-17 rather than PKC/CPI-17
por: Yoon, Hyuk-Jun, et al.
Publicado: (2022)

3M No. 700 Black Watch 6250 CPI
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_nj6t0rkfdc57ti70sskjea0kjj